Katalin Prokai-Tatrai

Prof. Katalin Prokai-Tatrai

Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
Laszlo ProkaiLaszlo Prokai
Laszlo Prokai
Katalin Prokai-TatraiKatalin Prokai-Tatrai
Katalin Prokai-Tatrai
Pal PerjesiPal Perjesi
Pal Perjesi
AZAlevtina D. Zharikova
Alevtina D. Zharikova
EPEvelyn J. Perez
Evelyn J. Perez
JSJames W. Simpkins
James W. Simpkins
Substantial evidence now exists that intrinsic free-radical scavenging contributes to the receptor-independent neuroprotective effects of estrogens. This activity is inherently associated with the presence of a phenolic A-ring in the steroid. We report a previously unrecognized antioxidant cycle that maintains the “chemical shield” raised by estrogens against the most harmful reactive oxygen species, the hydroxyl radical (•OH) produced by the Fenton reaction. In this cycle, the capture of •OH was shown to produce a nonphenolic quinol with no affinity to the estrogen receptors. This quinol is then rapidly converted back to the parent estrogen via an enzyme-catalyzed reduction by using NAD(P)H as a coenzyme (reductant) and, unlike redox cycling of catechol estrogens, without the production of reactive oxygen species. Due to this process, protection of neuronal cells against oxidative stress is also possible by quinols that essentially act as prodrugs for the active hormone. We have shown that the quinol obtained from a 17β-estradiol derivative was, indeed, able to attenuate glutamate-induced oxidative stress in cultured hippocampus-derived HT-22 cells. Estrone quinol was also equipotent with its parent estrogen in reducing lesion volume in ovariectomized rats after transient middle carotid artery occlusion followed by a 24-h reperfusion. These findings may establish the foundation for a rational design of neuroprotective antioxidants focusing on steroidal quinols as unique molecular leads.

2 August 2000 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
Laszlo ProkaiLaszlo Prokai
Laszlo Prokai
Katalin Prokai-TatraiKatalin Prokai-Tatrai
Katalin Prokai-Tatrai
NBNicholas Bodor
Nicholas Bodor

1 January 2004 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
WKWilliam R. Kem
William R. Kem
VMVladimir M. Mahnir
Vladimir M. Mahnir
Laszlo ProkaiLaszlo Prokai
Laszlo Prokai
RPRoger L. Papke
Roger L. Papke
XCXuefang Cao
Xuefang Cao
FSFerenc Soti
Ferenc Soti
3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride (DMXBA; GTS-21), an Alzheimer9s drug candidate, selectively stimulates α7 nicotinic acetylcholine receptors. It rapidly enters the brain after oral administration and enhances cognitive behavior. Less than 1% of orally administered DMXBA is recovered in the urine. We report the identification and characterization of the major phase I metabolites of this drug candidate. Three hydroxy metabolites were generated in vitro by hepatic microsomal O-dealkylation of the two methoxy substituents on the benzylidene ring. They were also found in plasma of rats after oral administration, but at significantly lower concentrations relative to the parent compound. The metabolites displayed similar binding affinities and partial agonist potencies at rat brain α7 receptors. However, each displayed a higher efficacy than DMXBA for stimulating rat and human α7 receptors. Like DMXBA, the metabolites were weak antagonists at α4β2 receptors. The predicted conformations of the metabolites were nearly identical with that of DMXBA. Ionization of the tetrahydropyridyl nitrogen was essential for high-affinity binding of DMXBA to the α7 receptor. The hydroxy metabolites were much more polar than DMXBA, derived from their experimentally estimated octanol/water partition coefficients, and they entered the brain much less readily than DMXBA. Their contributions to the behavioral effects of orally administered DMXBA, if any, would probably be very small during short-term administration. Benzylidene anabaseines pharmacologically similar to the hydroxy metabolites, but which enter the brain more readily, may provide greater stimulation of α7 receptors in the whole organism.

10 July 2013 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
Katalin Prokai-TatraiKatalin Prokai-Tatrai
Katalin Prokai-Tatrai
HXHua Xin
Hua Xin
VNVien Nguyen
Vien Nguyen
SSSzabolcs Szarka
Szabolcs Szarka
BBBalazs Blazics
Balazs Blazics
PKPeter Koulen
Peter Koulen

22 July 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
Laszlo ProkaiLaszlo Prokai
Laszlo Prokai
VNVien Nguyen
Vien Nguyen
SSSzabolcs Szarka
Szabolcs Szarka
PGPuja Garg
Puja Garg
GSGauri Sabnis
Gauri Sabnis
Katalin Prokai-TatraiKatalin Prokai-Tatrai
Katalin Prokai-Tatrai
The bioprecursor prodrug 10β, 17β-dihydroxyestra-1,4-dien-3-one (DHED) allows 17β-estradiol to form in the female brain for neuroprotection and to treat neurological and psychiatric symptoms of menopause.

1 March 2008 in Steroids
Verified
Journal Article
Closed access
Katalin Prokai-TatraiKatalin Prokai-Tatrai
Katalin Prokai-Tatrai
Pal PerjesiPal Perjesi
Pal Perjesi
NRNilka M. Rivera-Portalatin
Nilka M. Rivera-Portalatin
JSJames W. Simpkins
James W. Simpkins
Laszlo ProkaiLaszlo Prokai
Laszlo Prokai